MYCOF (Noveris Health Sciences) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MYCOF Noveris Health Sciences Inc MYCOF
19 GF Score
Price $1.10
GF Value $0.52
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences Other Stockholders Equity?

Noveris Health Sciences MYCOF 19 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 19/100 and a GF Value™ of $0.52 (Significantly Overvalued).

Noveris Health Sciences's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

Noveris Health Sciences's quarterly Other Stockholders Equity declined from Sep. 2025 ($0.21 Mil) to Dec. 2025 ($0.00 Mil) and declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Noveris Health Sciences's annual Other Stockholders Equity declined from Dec. 2023 ($0.21 Mil) to Dec. 2024 ($0.20 Mil) and declined from Dec. 2024 ($0.20 Mil) to Dec. 2025 ($0.00 Mil).

Noveris Health Sciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Noveris Health Sciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noveris Health Sciences Other Stockholders Equity Chart

Noveris Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.13 0.21 0.20 0.00

Noveris Health Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.21 0.21 0.00 0.00
MYCOF
19GF Score
Noveris Health Sciences Inc MYCOF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noveris Health Sciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Noveris Health Sciences (MYCOF) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Noveris Health Sciences and its competitors.
Is Noveris Health Sciences' Other Stockholders Equity too high?
Noveris Health Sciences' current Other Stockholders Equity is $0.00 Mil. Overall, Noveris Health Sciences has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Other Stockholders Equity compare to ZTS and UTHR?
Noveris Health Sciences' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Noveris Health Sciences and its competitors. Noveris Health Sciences's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $1.10 — trading 111.5% above its estimated fair value. The current Other Stockholders Equity is $0.00 Mil. Noveris Health Sciences' overall GF Score™ is 19/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noveris Health Sciences (MYCOF) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of $1.10 is trading 111.5% above its estimated GF Value™ of $0.52. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for MYCOF:

  • Other Stockholders Equity: $0.00 Mil
  • GF Value™: $0.52 vs. price of $1.10 (111.5% above fair value)
  • GF Score™: 19/100

No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noveris Health Sciences Business Description

Other Exchanges 0NF1:GermanyNVRS:Canada
Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
19GF Score

Get the complete analysis for MYCOF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.10
Price
$0.52
GF Value